Marken Prepared For Growth In China Marken Receives Extended License, Expands Infrastructure, and Enhances Staff Training
RESEARCH TRIANGLE PARK, N.C., Oct. 2, 2012 /PRNewswire/ -- Marken announced today that it continues its expansion in China to meet the anticipated need for increased clinical trials logistics services.
Marken has been granted a 12 year license to ship biological samples and drug product within China. In addition, Marken continues to grow its Chinese presence by adding more experts to its already existing team. The staff is trained and fully certified on IATA regulations and anti-corruption policies. Marken has also conducted a comprehensive compliance audit of all of its in-country agents. Marken also announced the start of its Phase II depot roll out plan as it has begun construction of its pharmaceutical depot at its new branch location near the Beijing International airport.
Asia is the fastest growing region for new clinical trials. Analysts predict that China clinical trials will grow at 20% over the next several years which will allow it to rival Japan and Korea as key hubs for pharmaceutical R&D. Marken continues significant investments in these countries to further enhance its already solid base in Singapore, India, South Korea, Japan and Australia.
Wes Wheeler, Chief Executive Officer of Marken said, "We recognize the value of the clinical trial market in Asia and what economic impact the region has for many of our pharmaceutical clients. China, Korea and Japan are now clearly in focus for Marken and we will continue to analyze and anticipate new opportunities, both within China as well as other parts of Asia and the world as a whole."
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.